FTC Sides With Amneal Over Inhaler Patent Dispute With Teva
FTC’s Amicus Brief Called Teva’s Arguments “Unavailing And Inconsistent With The Statute”
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
